EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

R-DA-EPOCH Versus DA-EPOCH-R: Impact of Chemoimmunotherapy Sequencing on Treatment Outcomes in Patients With Diffuse Large B-Cell Lymphoma

Benjamin J Lee, Shawn P Griffin, Jean Doh, Anthony Quach, Yujiao Sun, Elizabeth A Brem, Richard A Van Etten, Edward L Nelson, Catherine C Coombs, Alexandre Chan

Clinical Lymphoma Myeloma and Leukemia · 2025

DOI: 10.1016/j.clml.2025.06.018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Benjamin J Lee und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of California Irvine Health, Orange, CA; Department of Clinical Pharmacy Practice, School of Pharmacy & Pharmaceut…. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Antineoplastic Combined Chemotherapy Protocols, Immunotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Chemoimmunotherapy with rituximab (R) added to dose-adjusted (DA)-EPOCH (continuous infusion of etoposide, vincristine, and doxorubicin with cyclophosphamide and prednisone) has become a standard treatment approach for high-risk diffuse large B-cell lymphoma (DLBCL) patients. In contrast to pivotal trials that sequenced rituximab with the initiation of each chemoimmunotherapy cycle, our institution adopted delaying rituximab following discharge after EPOCH completion in patients requiring inpatient chemotherapy (DA-EPOCH-R). Herein, we evaluate the efficacy and safety of rituximab sequencing with EPOCH initiation and after EPOCH administration. PATIENTS AND METHODS: A retrospective chart review of all DLBCL patients who received first-line treatment with R-DA-EPOCH or DA-EPOCH-R between 2016 and 2023 was conducted. Outcomes of interest included progression-free survival (PFS), overall response rate (ORR), complete response (CR), overall survival (OS), and cumulative incidence of relapse. RESULTS: A total of 31 DA-EPOCH-R and 35 R-DA-EPOCH patients were included. PFS at 4-years was not significantly different between DA-EPOCH-R and R-DA-EPOCH treated patients (75.2% vs. 77.9%; HR 1.10; 95% CI, 0.38-3.13; P = .86). ORR (93.5% vs. 100%; P = .22) and CR (90.3% vs. 85.7%; P = .71) were also similar between cohorts. Rituximab-related infusion reactions were higher among R-DA-EPOCH-treated patients with cycle 1 (P = .038). CONCLUSION: Our findings suggest delaying rituximab following EPOCH did not affect treatment outcomes and are associated with lower infusion reactions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseAntineoplastic Combined Chemotherapy ProtocolsImmunotherapyHumansMaleFemaleMiddle AgedCyclophosphamideVincristineDoxorubicinRetrospective StudiesAgedPrednisoneEtoposideTreatment OutcomeAdultRituximabAged, 80 and over

Stichwörter der Autor:innen

DLBCLEPOCHHigh-grade lymphomaRituximab

Substanzen

CyclophosphamideVincristineDoxorubicinPrednisoneEtoposideRituximab

Autor:innen und Institutionen

  • Department of Pharmacy, University of California Irvine Health, Orange, CA; Department of Clinical Pharmacy Practice, School of Pharmacy & Pharmaceutical Sciences, University of California, Irvine, CA. Electronic addres…
  • Department of Pharmacy, University of California Irvine Health, Orange, CA; Department of Clinical Pharmacy Practice, School of Pharmacy & Pharmaceutical Sciences, University of California, Irvine, CA.
  • Department of Pharmacy, University of California Irvine Health, Orange, CA.
  • Department of Medicine, Division of Hematology Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Health, Orange, CA.
  • Department of Pharmacy, University of California Irvine Health, Orange, CA; Department of Clinical Pharmacy Practice, School of Pharmacy & Pharmaceutical Sciences, University of California, Irvine, CA; Department of Med…

Förderung

  • NCI NIH HHS

Zitieren

APA

Lee, B. J., Griffin, S. P., Doh, J., Quach, A., Sun, Y., Brem, E. A., Van Etten, R. A., Nelson, E. L., Coombs, C. C., & Chan, A. (2025). R-DA-EPOCH Versus DA-EPOCH-R: Impact of Chemoimmunotherapy Sequencing on Treatment Outcomes in Patients With Diffuse Large B-Cell Lymphoma. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.06.018

Vancouver

Lee BJ, Griffin SP, Doh J, Quach A, Sun Y, Brem EA, et al. R-DA-EPOCH Versus DA-EPOCH-R: Impact of Chemoimmunotherapy Sequencing on Treatment Outcomes in Patients With Diffuse Large B-Cell Lymphoma. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2025.06.018

BibTeX
@article{Lee2025,
  author = {Lee, Benjamin J and Griffin, Shawn P and Doh, Jean and Quach, Anthony and Sun, Yujiao and Brem, Elizabeth A and Van Etten, Richard A and Nelson, Edward L and Coombs, Catherine C and Chan, Alexandre},
  title = {R-DA-EPOCH Versus DA-EPOCH-R: Impact of Chemoimmunotherapy Sequencing on Treatment Outcomes in Patients With Diffuse Large B-Cell Lymphoma},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2025},
  doi = {10.1016/j.clml.2025.06.018}
}
Kostenlos starten →